The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Abstract
Impairments in certain cognitive functions mediated by the dorsolateral prefrontal cortex, such as working memory, are core features of schizophrenia. Convergent findings suggest that these disturbances are associated with alterations in markers of inhibitory gamma-aminobutyric acid and excitatory glutamate neurotransmission in the dorsolateral prefrontal cortex. Specifically, reduced gamma-aminobutyric acid synthesis is present in the subpopulation of gamma-aminobutyric acid neurons that express the calcium-binding protein parvalbumin. Despite presynaptic and postsynaptic compensatory responses, the resulting impaired inhibitory regulation of pyramidal neurons contributes to a reduction in the synchronized neuronal activity that is required for working memory function. Several lines of evidence suggest that these changes may be either secondary to or exacerbated by impaired signaling via the N-methyl-d-aspartate class of glutamate receptors. These findings suggest specific targets for therapeutic interventions to improve cognitive function in individuals with schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diminished activation of NMDA-receptors results in insufficient excitatory activity, disrupting the monitoring function of GABAergic inhibitory neurons.”
From Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies (2013) · cites this paper as [80]
In the citing paper
“In response, these inhibitory neurons may downregulate their own activity.79,80”
From Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies (2013) · cites this paper as [80]
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [2]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Self-citationSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Schizophrenia as a Disorder of Neurodevelopment
Lewis, D. A., & Levitt, P. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142754 · Cited by 1,163
Self-citationAkbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Self-citationCognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1×
“Although psychosis is usually the most striking clinical aspect of schizophrenia, disturbances in certain cognitive processes, such as attention, certain types of memory, and executive functions, are considered to be the core features of the illness.(4) Such cognitive disturbances (1) can be present for years before t…”
BackgroundLewis, D. A., & Lieberman, J. A. (2000) · Neuron · doi:10.1016/s0896-6273(00)00111-2 · Cited by 833
Self-citationGamma Oscillations Correlate with Working Memory Load in Humans
Howard, M. W. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg084 · Cited by 766
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.237 · Cited by 697
Self-citation
Cited by
Sorted by citations
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases
Mei, L., & Nave, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.007 · Cited by 616
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 627
The Hippocampal Formation in Schizophrenia
Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081187 · Cited by 597
Wang, M., Yang, Y., Wang, C.-J., Gamo, N. J., Jin, L. E., Mazer, J. A., Morrison, J. H., Wang, X.-J., & Arnsten, A. F. T. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.032 · Cited by 489
Logue, S. F., & Gould, T. J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.08.007 · Cited by 477
Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder
Baker, J. T., Holmes, A. J., Masters, G. A., Yeo, B. T. T., Krienen, F., Buckner, R. L., & Öngür, D. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3469 · Cited by 435
Anticevic, A., Haut, K. M., Murray, J. D., Repovš, G., Yang, G., Diehl, C., McEwen, S. C., Bearden, C. E., Addington, J., Goodyear, B. G., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0566 · Cited by 387
Lui, S., Li, T., Deng, W., Jiang, L., Wu, Q., Tang, H., Yue, Q., Huang, X., Chan, R. C. K., Collier, D. A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.84 · Cited by 365
Conn, P. J., Lindsley, C. W., & Jones, C. K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330
Haenschel, C., Bittner, R. A., Waltz, J., Haertling, F., Wibral, M., Singer, W., Linden, D. E. J., & Rodriguez, E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1428-09.2009 · Cited by 303
Calcium ions in neuronal degeneration
Wojda, U., Salińska, E., & Kuźnicki, J. (2008) · IUBMB Life · doi:10.1002/iub.91 · Cited by 303
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
Kehrer, C. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.006.2008 · Cited by 287
General and Specific Cognitive Deficits in Schizophrenia: Goliath Defeats David?
Dickinson, D., Ragland, J. D., Gold, J. M., & Gur, R. C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.005 · Cited by 296
Meyer, U., Schwarz, M., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 262
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Glutamatergic theories of schizophrenia.
Javitt, D. C. (2010) · PubMed · Cited by 248
Minzenberg, M. J., Firl, A. J., Yoon, J. H., Gomes, G. C., Reinking, C., & Carter, C. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.150 · Cited by 247
Moghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238
Self-citationNMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
Snyder, M. A., & Gao, W. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00031 · Cited by 254
Effect of second-generation antipsychotics on cognition: current issues and future challenges
Hill, S. K., Bishop, J. R., Palumbo, D. R., & Sweeney, J. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.143 · Cited by 236
Cohen, S. M., Tsien, R. W., GOFF, D. C., & Halassa, M. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.026 · Cited by 249
Jones, C. K., Byun, N. E., & Bubser, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.199 · Cited by 241
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 227
Treating Working Memory Deficits in Schizophrenia: A Review of the Neurobiology
Lett, T. A., Voineskos, A. N., Kennedy, J. L., Levine, B., & Daskalakis, Z. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.026 · Cited by 257
GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders
Sibille, E., Morris, H. M., Kota, R. S., & Lewis, D. A. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001616 · Cited by 217
Self-citationModulators in concert for cognition: Modulator interactions in the prefrontal cortex
Briand, L. A., Gritton, H., Howe, W. M., Young, D. A., & Sarter, M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.007 · Cited by 216
Excitation control: balancing PSD-95 function at the synapse
Keith, D. J. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.004.2008 · Cited by 223
Ketamine Modulates Theta and Gamma Oscillations
Lazarewicz, M. T., Ehrlichman, R. S., Maxwell, C. R., Gandal, M. J., Finkel, L. H., & Siegel, S. J. (2009) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2009.21305 · Cited by 216
Bridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205
Arco, A. D., & Mora, F. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0243-8 · Cited by 211
Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines
Ali, F., Gerhard, D. M., Sweasy, K., Pothula, S., Pittenger, C., Duman, R. S., & Kwan, A. C. (2020) · Nature Communications · doi:10.1038/s41467-019-13809-8 · Cited by 196
GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies
de Jonge, J. C., Vinkers, C. H., Pol, H. E. H., & Marsman, A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00118 · Cited by 203
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
Karam, C. S., Ballon, J. S., Bivens, N. M., Freyberg, Z., Girgis, R. R., Lizardi-Ortiz, J. E., Markx, S., Lieberman, J. A., & Javitch, J. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.05.004 · Cited by 180
Uhlhaas, P. J., & Singer, W. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr034 · Cited by 176
Behan, Á., Byrne, C., Dunn, M. J., Cagney, G., & Cotter, D. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.7 · Cited by 145
The dynorphin/κ-opioid receptor system and its role in psychiatric disorders
Tejeda, H. A., Shippenberg, T. S., & Henriksson, R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0844-x · Cited by 161
Wood, J. T., Kim, Y., & Moghaddam, B. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6377-11.2012 · Cited by 152
Self-citationFunk, A. J., McCullumsmith, R. E., Haroutunian, V. H., & Meador‐Woodruff, J. H. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.267 · Cited by 161
Rotaru, D. C., Yoshino, H., Lewis, D. A., Ermentrout, G. B., & Gonzalez-Burgos, G. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1970-10.2011 · Cited by 151
Self-citationGABA and glutamate in schizophrenia: A 7 T 1H-MRS study
Marsman, A., Mandl, R. C. W., Klomp, D. W. J., Bohlken, M. M., Boer, V. O., Андрейченко, А. Е., Cahn, W., Kahn, R. S., Luijten, P. R., & Pol, H. E. H. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.10.005 · Cited by 159
Abnormal Long-Range Neural Synchrony in a Maternal Immune Activation Animal Model of Schizophrenia
Dickerson, D. D., Wolff, A. R., & Bilkey, D. K. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3046-10.2010 · Cited by 156
Lui, S., Huang, X., Chen, L., Tang, H., Zhang, T., Li, X., Li, D., Kuang, W., Chan, R. C. K., Mechelli, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812751106 · Cited by 147
Wu, H., Pereira, E. F. R., Bruno, J. P., Pellicciari, R., Albuquerque, E. X., & Schwarcz, R. M. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9235-2 · Cited by 146
Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models
O'Donnell, P. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr028 · Cited by 145
Microglial Pruning of Synapses in the Prefrontal Cortex During Adolescence
Mallya, A. P., Wang, H., Lee, H. N. R., & Deutch, A. Y. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy061 · Cited by 146
Tseng, K. Y., Lewis, B. L., Hashimoto, T., Sesack, S. R., Kloc, M., Lewis, D. A., & O'Donnell, P. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4166-08.2008 · Cited by 144
Self-citationTarget Identification for CNS Diseases by Transcriptional Profiling
Altar, C. A., Vawter, M. P., & Ginsberg, S. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.172 · Cited by 139
Reversal of Behavioral Deficits and Synaptic Dysfunction in Mice Overexpressing Neuregulin 1
Yin, D., Chen, Y., Lu, Y.-S., Bean, J. C., Sathyamurthy, A., Shen, C., Liu, X., Lin, T. W., Smith, C. A., Xiong, W., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.03.028 · Cited by 144
Early Sensory Contributions to Contextual Encoding Deficits in Schizophrenia
Dias, E. C., Butler, P. D., Hoptman, M. J., & Javitt, D. C. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.17 · Cited by 139
Dickinson, D., & Harvey, P. D. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn097 · Cited by 138
Groves, N. J., Kesby, J. P., Eyles, D. W., McGrath, J. J., Mackay‐Sim, A., & Burne, T. H. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.001 · Cited by 134
Brain Neuroplasticity in Healthy, Hyperactive and Psychotic Children: Insights from Neuroimaging
Rapoport, J. L., & Gogtay, N. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301553 · Cited by 132
Development of Patient-Specific Neurons in Schizophrenia Using Induced Pluripotent Stem Cells
Pedrosa, E., Sandler, V. M., Shah, A., Carroll, R. C., Chang, C.-J., Rockowitz, S., Guo, X., Zheng, D., & Lachman, H. M. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.597908 · Cited by 129
Yang, C. R., & Svensson, K. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.004 · Cited by 129
The possible role of the Akt signaling pathway in schizophrenia
Zheng, W., Wang, H., Zeng, Z., Lin, J., Little, P. J., Srivastava, L. K., & Quirion, R. (2012) · Brain Research · doi:10.1016/j.brainres.2012.06.032 · Cited by 130
Mcomish, C., Burrows, E., Howard, M., Scarr, E., Kim, D., Shin, H.-S., Dean, B., van den Buuse, M., & Hannan, A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002046 · Cited by 136
Holland, F. H., Ganguly, P., Potter, D. N., Chartoff, E. H., & Brenhouse, H. C. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.02.023 · Cited by 125
Tang, J., LeGros, R., Louneva, N., Yeh, L., Cohen, J., Hahn, C.-G., Blake, D. J., Arnold, S. E., & Talbot, K. (2009) · Nature Precedings · doi:10.1093/hmg/ddp329 · Cited by 125
Structural and metabolic changes in language areas linked to formal thought disorder.
Horn, H., Federspiel, A., Wirth, M., Müller, T. J., Wiest, R., Wang, J.-J., & Strik, W. (2009) · The British journal of psychiatry : the journal of mental science · doi:10.1192/bjp.bp.107.045633 · Cited by 124
Early Cognitive Experience Prevents Adult Deficits in a Neurodevelopmental Schizophrenia Model
Lee, H., Dvorak, D., Kao, H.-Y., Duffy, Á. M., Scharfman, H. E., & Fenton, A. A. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.016 · Cited by 122
Astrocyte‐derived kynurenic acid modulates basal and evoked cortical acetylcholine release
Zmarowski, A., Wu, H., Brooks, J. M., Potter, M. C., Pellicciari, R., Schwarcz, R. M., & Bruno, J. P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06594.x · Cited by 121
Mismatch Negativity: Translating the Potential
Todd, J., Harms, L. R., Schall, U., & Michie, P. T. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00171 · Cited by 123
Contributions of the d-serine pathway to schizophrenia
Labrie, V., Wong, A. H. C., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.030 · Cited by 121
Kantrowitz, J. T., & Javitt, D. C. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.6 · Cited by 120
Gamma oscillations in schizophrenia: Mechanisms and clinical significance
Sun, Y., Farzan, F., Barr, M. S., Kirihara, K., Fitzgerald, P. B., Light, G. A., & Daskalakis, Z. J. (2011) · Brain Research · doi:10.1016/j.brainres.2011.06.065 · Cited by 123
Meehan, C. L., Harms, L. R., Frost, J. D., Barreto, R., Todd, J., Schall, U., Weickert, C. S., Zavitsanou, K., Michie, P. T., & Hodgson, D. M. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.07.144 · Cited by 121
Insights into Cortical Oscillations Arising from Optogenetic Studies
Sohal, V. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.024 · Cited by 118
de Almeida, J., & Mengod, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04768.x · Cited by 111
Murphy, E. R., Fernando, A. B. P., Urcelay, G. P., Robinson, E. S. J., Mar, A. C., Theobald, D. E. H., Dalley, J. W., & Robbins, T. W. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2572-1 · Cited by 115
The Major Histocompatibility Complex (MHC) in Schizophrenia: A Review
Mokhtari, R., & Lachman, H. M. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000479 · Cited by 117
NCAM in Neuropsychiatric and Neurodegenerative Disorders
Brennaman, L. H., & Maness, P. F. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1170-4_19 · Cited by 111
Pezze, M. A., McGarrity, S., Mason, R., Fone, K. C. F., & Bast, T. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3450-13.2014 · Cited by 106
Deciphering the Disease Process of Schizophrenia: The Contribution of Cortical Gaba Neurons
Lewis, D. A., & Hashimoto, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78004-7 · Cited by 106
Self-citationParellada, E., & Gassó, P. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01385-9 · Cited by 108
Liu, X., Hashimoto‐Torii, K., Torii, M., Haydar, T. F., & RAKIC, P. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805180105 · Cited by 104
Bangalore, S. S., Prasad, K. M. R., Montrose, D. M., Goradia, D. D., Diwadkar, V. A., & Keshavan, M. S. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.029 · Cited by 100
Wing, V. C., Wass, C., Soh, D. W., & George, T. P. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06261.x · Cited by 99
Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition
Bast, T., Pezze, M. A., & McGarrity, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13850 · Cited by 99
Gamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
Rowland, L. M., Summerfelt, A. T., Wijtenburg, S. A., Du, X. M., Chiappelli, J., Krishna, N., West, J., Muellerklein, F., Kochunov, P. V., & Hong, L. E. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2680 · Cited by 96
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Hovelsø, N., Sotty, F., Montezinho, L. P., Pinheiro, P. S., Herrik, K. F., & Mørk, A. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362805 · Cited by 100
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Fišar, Z. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110626 · Cited by 103
NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms
Snyder, M. A., & Gao, W. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.010 · Cited by 97
Gildawie, K. R., Honeycutt, J. A., & Brenhouse, H. C. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.010 · Cited by 90
Konradsson‐Geuken, Å., Wu, H., Gash, C. R., Alexander, K., Campbell, A., Sozeri, Y., Pellicciari, R., Schwarcz, R. M., & Bruno, J. P. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.052 · Cited by 96
Piontkewitz, Y., Bernstein, H., Dobrowolny, H., Bogerts, B., Weiner, I., & Keilhoff, G. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.11.004 · Cited by 93
Losing inhibition with ketamine
Seamans, J. K. (2008) · Nature Chemical Biology · doi:10.1038/nchembio0208-91 · Cited by 92
Roalf, D. R., Nanga, R. P. R., Rupert, P. E., Hariharan, H., Quarmley, M., Calkins, M. E., Dress, E. M., Prabhakaran, K., Elliott, M. A., Moberg, P. J., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.258 · Cited by 92
Kristiansen, L. V., Patel, S. A., Haroutunian, V. H., & Meador‐Woodruff, J. H. (2010) · Synapse · doi:10.1002/syn.20754 · Cited by 87
Iltis, I., Koski, D. M., Eberly, L. E., Nelson, C. D., Deelchand, D. K., Valette, J., Uǧurbil, K., Lim, K. O., & Henry, P. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1385 · Cited by 83
Cabungcal, J.-H., Preissmann, D., Delseth, C., Cuénod, M., Kim, Q., & Schenk, F. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.03.001 · Cited by 83
Giovanoli, S., Weber, L., & Meyer, U. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.04.005 · Cited by 82
Testing the glutamate hypothesis of schizophrenia
Gordon, J. A. (2009) · Nature Neuroscience · doi:10.1038/nn0110-2 · Cited by 81
Stan, A. D., Ghose, S., Zhao, C., Hulsey, K., Mihalakos, P., Yanagi, M., Morris, S., Bartko, J. J., Choi, C., & Tamminga, C. A. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.54 · Cited by 79
Chue, P. S., & Lalonde, J. K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s43404 · Cited by 77
Metadata
- Authors
- Lewis, D. A., & Moghaddam, B.
- Affiliations
- University of Pittsburgh (US)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-10-01
- Volume
- 63
- Issue
- 10
- Pages
- 1372
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2037549116
- Cited by
- 404
- References
- 41
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 11 · 2023: 6 · 2022: 9 · 2021: 11 · 2020: 11 · 2019: 12 · 2018: 16 · 2017: 13 · 2016: 17 · 2015: 22 · 2014: 28 · 2013: 25 · 2012: 39
- FWCI
- 20.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pittsburgh
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01mh048404-30, MH043784, MH045156)
- National Institute of Mental Health (MH-045156, R01-MH048404, MH051234, R37MH048404, R01MH051234, P50MH045156, MH065026, R21MH065026, MH043784, MH048404)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, cognitive impairment, working memory, dorsolateral prefrontal cortex, GABAergic inhibition, glutamatergic excitation, parvalbumin, NMDA receptor, neuronal synchronization, therapeutic target
- MeSH terms
- Animals, Cognition Disorders, gamma-Aminobutyric Acid, Humans, Neural Inhibition, Synaptic Transmission, Schizophrenia, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Pyramidal Cells, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review